Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Arcturus Therapeutics Holdings Inc is a biotechnology business based in the US. Arcturus Therapeutics shares (ARCT) are listed on the NASDAQ and all prices are listed in US Dollars. Arcturus Therapeutics employs 118 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Long-term investors
Our top pick for
Beginners
Our top pick for
Active traders
| Latest market close | $24.59 |
|---|---|
| 52-week range | $24.87 - $89.18 |
| 50-day moving average | $37.66 |
| 200-day moving average | $39.57 |
| Wall St. target price | $85.45 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-7.56 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $24.59 from 2022-01-21
| 1 week (2022-01-14) | -26.55% |
|---|---|
| 1 month (2021-12-22) | -42.34% |
| 3 months (2021-10-22) | -44.75% |
| 6 months (2021-07-22) | -21.91% |
| 1 year (2021-01-22) | -63.68% |
|---|---|
| 2 years (2020-01-22) | 98.79% |
| 3 years (2019-01-22) | 397.78% |
| 5 years (2017-01-20) | 2,383.84% |
| Revenue TTM | $8.8 million |
|---|---|
| Gross profit TTM | $-48,307,000 |
| Return on assets TTM | -32.41% |
| Return on equity TTM | -75.32% |
| Profit margin | 0% |
| Book value | $9.83 |
| Market capitalisation | $882.5 million |
TTM: trailing 12 months
We're not expecting Arcturus Therapeutics to pay a dividend over the next 12 months.
Arcturus Therapeutics's shares were split on a 1:7 basis on 15 November 2017. So if you had owned 7 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Arcturus Therapeutics shares – just the quantity. However, indirectly, the new 600% higher share price could have impacted the market appetite for Arcturus Therapeutics shares which in turn could have impacted Arcturus Therapeutics's share price.
Over the last 12 months, Arcturus Therapeutics's shares have ranged in value from as little as $24.87 up to $89.1809. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Arcturus Therapeutics's is 2.631. This would suggest that Arcturus Therapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Arcturus Therapeutics Holdings Inc. , an RNA medicines company, focuses on the treatment of liver and respiratory care diseases. Its preclinical drug discovery and development programs include LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lung disease caused by mutations in cystic fibrosis transmembrane conductance regulator (CFTR) gene. The company owns LUNAR and nucleic acid technologies that are covered by a patent portfolio of 209 patents and patent applications, issued in the United States and other countries. It has collaboration partnerships with Ultragenyx Pharmaceutical, Inc. to develop mRNA therapeutic candidates for certain rare disease targets; Millennium Pharmaceuticals, Inc. (Takeda) to develop a nucleic acid-based therapeutic candidate for the treatment of nonalcoholic steatohepatitis; Janssen Pharmaceuticals, Inc.
Read our expert analysis on Vigorus and how the token will perform in the future.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
Starting Jan. 18, every household can order up to four free at-home COVID-19 tests. But you’ll have to wait for them.
While there are no known plans to expand the acceptance of Doge to its cars, customers can already buy a Tesla with Bitcoin.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
Donut earns up to 10% APY, but you must have an iOS device.
Monie offers 5% APY on deposits, but funds aren’t insured and the interface is buggy.
We’ve rounded up stats on some of the most popular COVID test stocks, along with information on how they compare and how to invest.
Record vehicle deliveries cause the Tesla stock price to move close to all-time highs.